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Aims Brown fat activation accelerates the uptake of cholesterol-enriched remnants by the liver and thereby lowers
plasma cholesterol, consequently protecting against atherosclerosis development. Hepatic cholesterol is then
converted into bile acids (BAs) that are secreted into the intestine and largely maintained within the enterohepatic
circulation. We now aimed to evaluate the effects of prolonged brown fat activation combined with inhibition of in-




APOE*3-Leiden.CETP mice with humanized lipoprotein metabolism were treated for 9 weeks with the selective b3-adre-
nergic receptor (AR) agonist CL316,243 to substantially activate brown fat. Prolonged b3-AR agonism reduced faecal
BA excretion (-31%), while markedly increasing plasma levels of total BAs (þ258%), cholic acid-derived BAs (þ295%),
and chenodeoxycholic acid-derived BAs (þ217%), and decreasing the expression of hepatic genes involved in BA pro-
duction. In subsequent experiments, mice were additionally treated with the BA sequestrant Colesevelam to inhibit BA
reabsorption. Concomitant intestinal BA sequestration increased faecal BA excretion, normalized plasma BA levels,
and reduced hepatic cholesterol. Moreover, concomitant BA sequestration further reduced plasma total cholesterol
(-49%) and non-high-density lipoprotein cholesterol (-56%), tended to further attenuate atherosclerotic lesion area
(-54%). Concomitant BA sequestration further increased the proportion of lesion-free valves (þ34%) and decreased
the relative macrophage area within the lesion (-26%), thereby further increasing the plaque stability index (þ44%).
....................................................................................................................................................................................................
Conclusion BA sequestration prevents the marked accumulation of plasma BAs as induced by prolonged brown fat activation,
thereby further improving cholesterol metabolism and reducing atherosclerosis development. These data suggest
that combining brown fat activation with BA sequestration is a promising new therapeutic strategy to reduce hyper-
lipidaemia and cardiovascular diseases.
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1. Introduction
Atherosclerosis represents the most common cause of cardiovascular
diseases. A prominent risk factor for atherosclerosis is hyperlipidaemia,
i.e. high levels of low-density lipoprotein cholesterol (LDL-C) and trigly-
cerides (TG) in the circulation. Currently, reducing circulating athero-
genic lipoproteins with lipid-lowering medication, such as statins and
PCSK9 inhibitors, remains the major strategy to prevent acute
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cardiovascular events. However, only 30% of all cardiovascular events
can be prevented by such treatment strategies,1 illustrating the need for
new therapeutic strategies.
Brown fat is present in mammals as well as in (adult) humans and is an
emerging target to combat hyperlipidaemia and atherosclerosis.2–4 Cold
exposure, the best known physiological activator of brown fat, leads to
the release of noradrenalin from sympathetic nerves that innervate
brown fat. Noradrenalin binds to the b3-adrenergic receptor (b3-AR)
on brown adipocytes, resulting in their activation to produce heat.5 As
the b3-AR is highly expressed on brown and white adipocytes, and white
fat does not substantially contribute to energy expenditure, the cold-
stimulated activation of brown fat inducing thermogenesis can be phar-
macologically mimicked by selective b3-AR agonists such as CL316,243
compound, one of the most selective b3-AR agonists available.6 Since
heat generation is an energy consuming process, activated brown fat
takes up large amounts of nutrients from the circulation, mainly TG-
derived fatty acids from TG-rich lipoproteins [TRLs; i.e. very-low-density
lipoproteins (VLDL) and chylomicrons].7,8 As a result, brown fat activa-
tion accelerates the formation and uptake of cholesterol-enriched lipo-
protein remnants by the liver, thereby protecting from hyperlipidaemia
and atherosclerosis development.7 In addition to reducing cholesterol-
enriched TRL remnant levels, b3-AR agonism also improves high-density
lipoprotein (HDL) functionality as reflected by increased reverse choles-
terol transport (RCT).7,9 Collectively, these studies show that b3-AR
agonism increases cholesterol delivery towards the liver via both accel-
erating the clearance of cholesterol-enriched TRL remnants and improv-
ing HDL-mediated RCT.
Hepatic cholesterol turnover is mainly mediated by faecal excretion
as bile acids (BAs) and, to a lesser extent, by faecal excretion of neutral
sterols.10 Hepatocytes synthesize primary BAs, i.e. cholic acid (CA) and
chenodeoxycholic acid (CDCA), via the so-called classic pathway; while
CDCA can also be synthesized via an alternative pathway.11 In mice, but
not in humans, CDCA can be converted into more hydrophilic species,
the so-called muricholic acids (MCAs).12 Newly synthesized BAs are
temporarily stored in the gallbladder and are secreted into the duode-
num upon food ingestion to serve as detergents for absorption of
nutrients.13 By the enzymatic action of gut bacteria, part of the primary
BAs are converted into secondary BAs. In the terminal ileum, 95% of
BAs are reabsorbed by active transport with remaining BAs excreted in
faeces. Reabsorbed BAs mainly circulate back through the portal vein to
the liver completing one cycle of enterohepatic circulation.14 BA synthe-
sis is regulated by enterohepatic circulation of BAs via farnesoid X recep-
tor (FXR), which inhibits transcription of genes in BA synthesis.15 The
enterohepatic circulation can be interrupted by BA sequestrants, which
increases clearance of plasma (V)LDL-C by promoting conversion of he-
patic cholesterol into BAs and up-regulation of hepatic LDL receptors.
In fact, BA sequestrants such as Cholestyramine and Colesevelam have
been proven to be effective to treat dyslipidaemia and prevent cardio-
vascular diseases.16
Interestingly, both short-term and long-term activation of brown fat
increases cholesterol delivery towards the liver.7,17 Moreover, we previ-
ously showed that long-term activation of brown fat significantly in-
creased hepatic cholesterol accumulation.17 Since BA synthesis is the
main pathway for hepatic cholesterol catabolism, short-term activation
of brown fat indeed has been linked to increased BA production and in-
creased faecal BA excretion.18 However, how long-term brown fat acti-
vation influences BA metabolism and whether manipulation of BA
metabolism on top of brown fat activation would lead to additional ben-
efits on cholesterol metabolism and atherosclerosis development has
not been studied yet. Thus, the aim of the current study was to evaluate
the effects of prolonged brown fat activation via b3-AR agonism on cho-
lesterol and BA metabolism. In addition, we assessed whether inhibiting
intestinal BA reabsorption beneficially influences the effects of prolonged
b3-AR agonism on cholesterol turnover and atherosclerosis develop-
ment. To this end, we treated hyperlipidaemic APOE*3-Leiden(E3L).CETP
mice, a well-established model for human-like lipoprotein metabolism
and atherosclerosis,19,20 with or without the selective b3-AR agonist
CL316,243 to activate brown fat for 9 weeks. In subsequent experi-
ments, E3L.CETP mice were treated with vehicle, CL316,243 alone, the
BA sequestrant Colesevelam alone to inhibit intestinal BA reabsorption,
or the combination of both for a period of 4 or 12 weeks.
2. Methods
Detailed description of the Methods section is available in the
Supplementary material online.
2.1 Animals and treatments
Hemizygous APOE*3-Leiden (E3L) mice were crossbred with homozy-
gous human cholesteryl ester transfer protein (CETP) transgenic mice
to generate heterozygous E3L.CETP mice.21 At the age of 10–12 weeks,
female mice were fed a Western-type diet (WTD; Altromin, Germany)
containing 15% cacao butter, 1% corn oil, and 0.15% (w/w) cholesterol.
In a first experiment,17 mice were randomized into two groups after a
run-in period of 6 weeks on WTD. Mice were subsequently treated
5 days/week with the selective b3-AR agonist CL316,243 (symbol: b;
Tocris Bioscience Bristol, UK; 20 lgmouse-1) or vehicle (phosphate-
buffered saline, symbol: –) by subcutaneous injections between 14:00
and 16:00 h for an additional 9 weeks.
In a second experiment, mice were randomized into two groups after
a run-in period of 3 weeks on WTD and subsequently received WTD
supplemented without or with 0.15% (w/w) Colesevelam (symbol: c;
Genzyme Europe B.V., The Netherlands). After an additional run-in pe-
riod of 3 weeks, mice in each treatment group were again randomized
into two subgroups and additionally treated 5 days/week with vehicle or
CL316,243 by subcutaneous injection for additional 4 weeks. This
resulted in the following four treatment groups: (i) vehicle (–), (ii)
CL316,243 (b), (iii) Colesevelam (c), and (iv) Colesevelamþ CL316,243
(cþb).
In a third experiment, the set-up was similar to the second experi-
ment, with the exception that mice were treated with CL316,243 or ve-
hicle for 12 weeks.
Food intake and body weight were monitored weekly. Body composi-
tion (i.e. body fat and lean mass; EchoMRI-100; EchoMRI, Houston, TX,
USA) was evaluated every 2 weeks. At the end of each experiment, mice
were euthanatized by CO2 suffocation and unconscious mice were per-
fused with ice-cold saline via cardiac perfusion, and various organs were
isolated for further analysis.
These animal experiments were approved by the Animal Ethical
Committee of Leiden University Medical Center, Leiden, The
Netherlands (DEC 12252-02). All animal procedures were performed
conform to the guidelines from Directive 2010/63/EU of the European
Parliament on the protection of animals used for scientific purposes.
2.2 Faecal and plasma bile acid analysis
Faeces were collected over a 24-h period and dried at room tempera-
ture, weighed, and homogenized. BA composition was determined in an


































































































aliquot of faeces by gas–liquid chromatography (GC). Plasma BA profile
was measured using liquid chromatography tandem MS (LC-MS/MS).
2.3 Biliary bile acid collection and
composition analysis
Mice were anaesthetized by intraperitoneal injection with Hypnorm
(1 mLkg-1; Janssen Pharmaceuticals) and Diazepam (10 mgkg-1; Actavis).
The bile duct was ligated and the gallbladder was cannulated to collect
BAs. Hepatic bile was collected for 15 min and the average of bile flow
per minute was calculated. BA compositions were determined in 5 lL
bile by GC as described above. Biliary cholesterol levels were deter-
mined using an enzymatic kit from Roche Diagnostics (Mannheim,
Germany).
2.4 Gene expression analysis
Gene expression analysis was performed as described in the
Supplementary material online. The primer sequences used are listed in
Supplementary material online, Table S1.
2.5 Plasma lipid assays and lipoprotein
profiles
Plasma was assayed for TG and total cholesterol (TC) using enzymatic
kits from Roche Diagnostics (Mannheim, Germany) as described in the
Supplementary material online. The distribution of TG and cholesterol
over lipoproteins was determined in pooled plasma by fast-performance
liquid chromatography (FPLC) using a Superose 6 column (GE
Healthcare, Piscataway, NJ, USA).
2.6 Hepatic lipid content
Liver lipids were assayed as described in the Supplementary material
online.
2.7 In vivo plasma decay and hepatic uptake
of TG-rich lipoprotein-like particles
TRL-like particles (80 nm), double-labelled with glycerol tri[3H]oleate
([3H]TO) and [14C]cholesteryl oleate ([14C]CO), were prepared as de-
scribed previously.22 Mice were fasted for 4 h and injected (t = 0) intrave-
nously with 200mL of TRL-like particles (1 mg TG per mouse). Blood
samples were taken from the tail vein at 2, 5, 10, and 15 min after injec-
tion to determine the plasma decay of [3H]TO and [14C]CO. After
15 min, livers were isolated and weighted, and 3H- and 14C-activity were
quantified.
2.8 Atherosclerosis quantification
Hearts were collected, fixed in phosphate-buffered 4% formaldehyde,
and embedded in paraffin. Four sections of the aortic root area with
50mm intervals were used and stained with haematoxylin–phloxine–saf-
fron for histological analysis. Lesions were categorized for lesion severity
according to the guidelines of the American Heart Association adapted
for mice23 and classified as mild lesions (types 1–3) and severe lesions
(types 4–5). Monoclonal mouse antibody M0851 against smooth muscle
cell (SMC) actin was used to quantify the SMC area, Sirius Red staining
was used to quantify the collagen area, and rat monoclonal antibody
MAC3 was used to quantify macrophage area as described.17 Lesion
area was determined with Image J Software (version 1.50i).
2.9 Statistical analysis
Differences between two groups were determined using the unpaired
two-tailed Student’s t-test. Differences between four groups were deter-
mined using one-way analysis of variance (ANOVA) with the LSD post
hoc test, which however increases the alpha risk as it does not correct
for multiple comparisons. The square root of the lesion area was trans-
formed to linearize the relationship with the plasma TC exposure.
Univariate regression of analyses was performed to test for significant
correlations between atherosclerotic lesion area and plasma TC expo-
sure. Multiple regression analysis was performed to predict the contribu-
tion of plasma TC exposures to the atherosclerotic lesion area.
Probability values less than 0.05 were considered statistically significant.
All statistical analyses were performed with the GraphPad Prism 7 for
Windows.
3. Results
3.1 Prolonged b3-AR agonism decreases
faecal bile acid excretion and increases
plasma bile acid levels
We previously fed female E3L.CETP mice a WTD and treated them with
the b3-AR agonist CL316,243 (b) or vehicle (–) for 9 weeks, and ob-
served that prolonged b3-AR agonism significantly increases liver TC lev-
els.17 Since BA synthesis is the major route of hepatic cholesterol
catabolism, we now analysed BAs level in faeces and plasma of this
9 weeks treatment study.17 Notably, prolonged b3-AR agonism reduced
faecal total BA output into faeces (-31%; Figure 1A), which equals hepatic
BA synthesis rate under steady-state conditions. While faecal CA-
derived BA secretion only tended to be reduced (-27%, P = 0.07;
Figure 1B), faecal CDCA-derived BA secretion was significantly reduced
(-35%; Figure 1C). The faecal excretion of secondary BAs was unaffected
(Figure 1D). In plasma, total BA levels were markedly increased (þ258%;
Figure 1E), and this was due to an increase in both CA-derived BAs
(þ295%; Figure 1F) and CDCA-derived BAs (þ217%; Figure 1G). b3-AR
agonism also increased plasma secondary BA levels (þ33%, Figure 1H),
and the proportion of conjugated BAs (þ55%, Supplementary material
online, Figure S1A). Collectively, these data suggest that prolonged b3-
AR agonism decreases faecal BA output related to stimulation of BA
reuptake.
3.2 Prolonged b3-AR agonism reduces the
expression of genes involved in bile acid
synthesis
To further reveal how b3-AR agonism regulates BA metabolism, hepatic
mRNA expression of genes involved in BA metabolism was investigated.
While b3-AR agonism only tended to reduce Cyp7a1, it significantly re-
duced Hsd3b7 (-57%) and Cyp8b1 (-40%) (Supplementary material on-
line, Figure S1B), all of which are involved in the classical BA synthesis
pathway. In addition, b3-AR agonism reduced Cyp27a1 (-53%) and
Cyp7b1 (-38%) (Supplementary material online, Figure S1C), which are in-
volved in the alternative BA synthesis pathway. This data is consistent
with the reduced faecal BA excretion, implying a reduced hepatic BA
synthesis rate under steady-state conditions. b3-AR agonism also tended
to reduce Abcg5 (-31%, P = 0.06) and Bsep expression (-27%, P = 0.05)
(Supplementary material online, Figure S1D), involved in excretion to-
wards the bile of sterols and BAs, respectively. On the other hand, b3-
AR agonism increased expression of Ost-b (þ64%; Supplementary














































..material online, Figure S1E), involved in the basolateral BA secretion
from the liver towards the systemic circulation. b3-AR agonism tended
to reduce Oatp1a1 expression (-60%, P = 0.06) and significantly reduced
Ntcp expression (-37%) (Supplementary material online, Figure S1F), in-
volved in the uptake of reabsorbed BAs by the liver.
3.3 Bile acid sequestration reverses b3-AR-
mediated reduction of faecal bile acid
output and normalizes elevated plasma
bile acid levels
Because we observed that b3-AR agonism decreases faecal BA excre-
tion and increases plasma BAs, we next assessed whether inhibition of
intestinal BA reabsorption, by using the BA sequestrant Colesevelam,
would stimulate faecal BA loss and prevent the increase in plasma BAs
during prolonged b3-AR agonism. Mice were treated for 4 weeks with
vehicle, the b3-AR agonist alone, a low dose of the BA sequestrant alone
(Colesevelam 0.15% in the WTD, w/w), or the combination of b3-AR
agonism and BA sequestration. b3-AR agonism, Colesevelam, or the
combination did not influence food intake (Supplementary material on-
line, Figure S2A), body weight (Supplementary material online, Figure
S2B), or body lean mass (Supplementary material online, Figure S2C). As
expected, b3-AR agonism tended to reduce body fat mass (P = 0.09;
Supplementary material online, Figure S2D) and significantly reduced go-
nadal white adipose tissue weight (gWAT; Supplementary material on-
line, Figure S2E). The combination of b3-AR agonism and BA
sequestration significantly reduced body fat mass (Supplementary mate-
rial online, Figure S2D) and gWAT weight (Supplementary material on-
line, Figure S2E) as compared to vehicle. Liver weight was not significantly
influenced by b3-AR agonism alone or in combination with BA seques-
tration (Supplementary material online, Figure S2F).
Compared to vehicle, b3-AR agonism alone, BA sequestration alone,
and the combination of b3-AR agonism and BA sequestration all in-
creased bile flow (þ43%, þ33%, and þ38% vs. vehicle, respectively;
Figure 2A). The biliary BA secretion rate was not influenced by the differ-
ent treatments (Figure 2B). Additionally, biliary cholesterol excretion
rate was increased by b3-AR agonism (þ75% vs. vehicle), but not by BA
sequestration or the combination of b3-AR agonism and BA sequestra-
tion (Figure 2C).
Furthermore, although 4 weeks b3-AR agonism did not significantly
decrease faecal excretion of total BAs (Figure 2D) and CA-derived BAs
(Figure 2E), excretion of CDCA-derived BAs was significantly decreased
(-50% vs. vehicle; Figure 2F). BA sequestration on top of b3-AR agonism
strongly increased faecal excretion of total BAs (þ91% vs. vehicle;
þ234% vs. b; þ47% vs. c; Figure 2D), CA-derived BAs (þ201% vs. vehi-
cle; þ357% vs. b; Figure 2E), and CDCA-derived BAs (þ109% vs. b;
Figure 2F). In addition, BA sequestration on top of b3-AR agonism mark-
edly increased faecal secondary BA excretion (þ122% vs. vehicle;
þ274% vs. b; þ40% vs. c; Figure 2G). Finally, although the b3-AR
agonism-induced increase in plasma BA levels was not as pronounced as
after 9 weeks of treatment, concomitant BA sequestration normalized
Figure 1 Prolonged b3-AR agonism decreases faecal bile acid excretion and increases plasma bile acid levels. E3L.CETP mice fed a WTD were treated
with the b3-AR agonist CL316,243 (b) or vehicle (–) for 9 weeks. During the last week of treatment, faeces were collected, and BA species were assayed.
Faecal excretion of (A) total bile acid (BAs), (B) cholic acid (CA)-derived BAs, (C) chenodeoxycholic acid (CDCA)-derived BAs, and (D) secondary BAs
were calculated; n = 7–8 mice/group. Plasma was collected and (E) total BAs, (F) CA-derived BAs, (G) CDCA-derived Bas, and (H) secondary BAs were de-
termined; n = 14–16 mice/group. Values are expressed as means ± SEM. Differences were determined using the unpaired two-tailed Student’s t-test.
*P < 0.05, **P < 0.01 vs. vehicle (–).







































these plasma BA levels (Figure 2H–J). b3-AR agonism clearly increased
plasma secondary BA levels (þ63% vs. vehicle), which was completely
reversed by BA sequestration (-118% vs. cþ b; Figure 2K). Taken to-
gether, these data indicate that inhibition of BA reabsorption by BA se-
questration reverses b3-AR agonism-induced reduction of faecal BA
excretion, i.e. stimulates hepatic BA synthesis under these conditions,
and normalizes b3-AR agonism-mediated increased plasma BA levels.
3.4 Bile acid sequestration on top of b3-AR
agonism reverses hepatic cholesterol
accumulation and further improves plasma
cholesterol levels
As the BA sequestrant Colesevelam on top of b3-AR agonism strongly
increased faecal BA excretion and normalized plasma BA levels, we eval-
uated whether the addition of BA sequestration could also correct the
b3-AR agonism-induced hepatic cholesterol accumulation as shown pre-
viously17 and further lower plasma lipids. We confirmed that b3-AR ago-
nism significantly increased hepatic TC levels (þ26%). BA sequestration
alone reduced hepatic TC levels as compared to vehicle (-41%)
(Figure 3A). Importantly, BA sequestration on top of b3-AR agonism also
largely reduced hepatic TC levels as compared to vehicle (-37%) and b3-
AR agonism alone (-50%) (Figure 3A), and to similar levels as BA seques-
tration alone. Hepatic TG and PL contents were not influenced by any of
the treatments (Figure 3B and C).
Next, we assessed the effect of BA sequestration on top of b3-AR
agonism on plasma lipid levels. After 4 weeks of treatment, plasma TG
levels were reduced by b3-AR agonism (-52%) and tended to be re-
duced by BA sequestration alone (-33%, P = 0.07) as compared to vehi-
cle. BA sequestration on top of b3-AR agonism reduced plasma TG
levels as compared to vehicle (-74%) and also as compared to BA se-
questration alone (-62%) (Figure 3D). In addition, BA sequestration alone
reduced plasma TC levels as compared to vehicle (-47%). BA sequestra-
tion on top of b3-AR agonism also reduced plasma TC levels as com-
pared to vehicle (-55%) and to b3-AR agonism alone (-49%; Figure 3E).
Since cholesterol can be carried in plasma by either pro- or athero-
genic lipoprotein classes, we also determined the distribution of choles-
terol over plasma non-HDL and HDL. Plasma non-HDL-C levels tended
to be reduced by b3-AR agonism alone (-27%, P = 0.05) and were signifi-
cantly reduced by BA sequestration alone (-55%) and BA sequestration
Figure 2 Bile acid sequestration reverses b3-AR induced reduction of faecal bile acid excretion and normalizes elevated plasma bile acid levels. E3L.CETP
mice fed a WTD were treated with vehicle (–), the b3-AR agonist CL316,243 (b), the bile acid (BA) sequestrant Colesevelam (c), or their combination
(cþb) for 4 weeks. Bile duct cannulation was performed to collect the bile and (A) bile flow (mL per minute) was determined. (B) BA secretion rate and (C)
cholesterol excretion rate in the bile were determined. Faeces were collected to determine faecal (D) total BAs, (E) cholic acid (CA)-derived BAs, (F) cheno-
deoxycholic acid (CDCA)-derived BAs, and (G) secondary BAs. In plasma, (H) total BAs, (I) CA-derived BAs, (J) CDCA-derived BAs, and (K) secondary BAs
were determined. N = 7–8 mice/group. Values are expressed as means ± SEM. Differences between four groups were determined using one-way ANOVA
with the LSD post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle (–); #P < 0.05, ##P < 0.01, ###P < 0.001 vs. b3-AR agonist (b); $P < 0.05, $$$P < 0.001
vs. Colesevelam (c).



















































on top of b3-AR agonism (-68%; Figure 3F) as compared to vehicle.
Moreover, BA sequestration on top of b3-AR agonism further reduced
non-HDL-C levels as compared to b3-AR agonism alone (-56%;
Figure 3F). In addition, both b3-AR agonism alone (þ34%), and in combi-
nation with BA sequestration (þ52%; Figure 3G) increased anti-
atherogenic HDL-C levels as compared to vehicle. Taken together, these
findings indicate that BA sequestration on top of b3-AR agonism
reverses the b3-AR agonism-induced hepatic cholesterol accumulation
and further reduces plasma non-HDL-C levels.
3.5 Bile acid sequestration does not
interfere with the b3-AR agonism-induced
plasma clearance and hepatic uptake of
cholesterol-enriched TRL remnants
As b3-AR agonism increases the formation and hepatic uptake of
cholesterol-enriched TRL remnants 7,17 and BA sequestration on top of
b3-AR agonism further lowers plasma non-HDL-C levels, we next stud-
ied whether BA sequestration on top of b3-AR agonism influenced the
hepatic uptake of cholesterol-enriched TRL remnants. Hereto, we
treated mice with the BA sequestrant Colesevelam on top of the b3-AR
agonist CL316,243 for 12 weeks. Similar as in the 4-week study, b3-AR
agonism alone and in combination with BA sequestration, but not BA se-
questration alone, reduced body fat mass (-37% and -38%, respectively;
Supplementary material online, Figure S3A) and gWAT weight (-55% and
-61%, respectively; Supplementary material online, Figure S3B) as com-
pared to vehicle. In agreement with previous studies,7,17 we also ob-
served that b3-AR agonism induced substantial brown fat activation and
browning of WAT as evidenced from decreased lipid contents in BAT
(Supplementary material online, Figure S3C) and subcutaneous WAT
(scWAT, Supplementary material online, Figure S3D), while BA seques-
tration on top of b3-AR agonism did not further add to these effects.
The mRNA expression of genes related to intestinal BA reabsorption in
the ileum is shown in Supplementary material online, Table S2. b3-AR
agonism significantly increased the mRNA expression of BA transporters
Asbt and Ost-b. Furthermore, b3-AR agonism markedly increased Shp
and Fgf15 mRNA expression in the ileum, while the expression of these
genes was reduced by BA sequestration, and normalized by the combi-
nation treatment.
In line with the 4-week intervention, 12 weeks of b3-AR agonism
alone improved dyslipidaemia by reducing plasma TG (-35%; Figure 4A),
mainly via reducing (V)LDL-TG (Figure 4B), TC (-31%; Figure 4C), and
non-HDL-C (-45%; Figure 4D) levels as compared to vehicle, while in-
creasing HDL-C levels (þ52%; Figure 4E). The decrease in (V)LDL-C
and increase in HDL-C by b3-AR agonism alone and on top of BA se-
questration was confirmed by FPLC (Figure 4F). As compared to b3-AR
agonism alone, BA sequestration on top of b3-AR agonism did not influ-
ence plasma TG (Figure 4A), but further lowered plasma TC (-24%;
Figure 4C) and tended to further reduce non-HDL-C levels (-32%,
P = 0.06; Figure 4D). Next, the total plasma TC and non-HDL-C expo-
sure during the treatment period were calculated. The combination
treatment further reduced both the total plasma TC exposure (-18%;
Figure 4G) and non-HDL-C exposure (-20%; Figure 4H) as compared to
b3-AR agonism alone.
After 12 weeks of treatment, we evaluated the plasma clearance and
hepatic uptake of intravenously injected glycerol tri[3H]oleate (triolein,
Figure 3 Bile acid sequestration on top of b3-AR agonism reverses hepatic cholesterol accumulation and further improves plasma cholesterol levels.
E3L.CETP mice fed a WTD were treated with vehicle (–), b3-AR agonist CL316,243 (b), bile acid sequestrant Colesevelam (c), or their combination (cþ b).
After 4 weeks treatment, mice were killed and liver samples were collected to evaluate hepatic (A) total cholesterol (TC), (B) triglyceride (TG), and (C)
phospholipid (PL) levels. Blood samples were collected and plasma was assayed for (D) TG, (E) TC, (F) non-HDL-cholesterol (non-HDL-C), and (G) HDL-
cholesterol (HDL-C) levels. N = 7–8 mice/group. Values are expressed as means ± SEM. Differences between four groups were determined using one-way
ANOVA with the LSD post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle (–); ###P < 0.001 vs. b3-AR agonist (b); $P < 0.05 vs. Colesevelam (c).
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Figure 4 Bile acid sequestration does not interfere with the b3-AR agonism-induced plasma clearance and hepatic uptake of cholesterol-enriched TRL
remnants. E3L.CETP mice fed a WTD were treated with vehicle (–), the b3-AR agonist CL316,243 (b), the bile acid sequestrant Colesevelam (c), or their
combination (cþ b). After 12 weeks treatment, blood was collected to determine plasma (A) triglycerides (TG), (B) distribution of TG over lipoproteins,
(C) total cholesterol (TC), (D) non-HDL-cholesterol (non-HDL-C), (E) HDL-cholesterol (HDL-C), and (F) distribution of TC over lipoproteins. (G) TC and
(H) non-HDL-C exposure were calculated; n = 13–16 mice/group. Mice were injected intravenously with glycerol tri[3H]oleate and [14C]cholesteryl oleate-
labelled lipoprotein-like particles. Plasma clearance of (I) 3H-activity and (J) 14C-activity, and (K) hepatic uptake of 14C-activity after 15 min were measured;
n = 6–9 mice/group. Values are expressed as means ± SEM. Differences between four groups were determined using one-way ANOVA with the LSD post
hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle (–); #P < 0.05, ##P < 0.01 vs. b3-AR agonist (b); $P < 0.05, $$$P < 0.001 vs. Colesevelam (c).


































































































TO) and [14C]cholesteryl oleate (CO) double-labelled VLDL-mimicking
particles. In line with previous studies,7,17 b3-AR agonism alone markedly
accelerated the plasma clearance of [3H]TO-derived activity (Figure 4I)
and [14C]CO (Figure 4J), and increased the hepatic uptake of the formed
cholesterol-enriched TRL remnants (þ25%, Figure 4K) as compared to
vehicle. Additional BA sequestration did not further accelerate the
plasma clearance of [3H]TO-derived activity and [14C]CO and also did
not further increase the hepatic uptake of [14C]CO (Figure 4I–K) as com-
pared to b3-AR agonism alone.
3.6 Bile acid sequestration on top of b3-AR
agonism tends to further attenuate
atherosclerosis development
To investigate if the beneficial effects of BA sequestration on top of b3-
AR agonism on BA and cholesterol metabolism would translate in a fur-
ther protection against atherosclerosis development, we evaluated the
atherosclerotic lesion area in the root of the aortic arch after 12 weeks
of treatment. As expected, b3-AR agonism alone decreased atheroscle-
rotic lesion area throughout the aortic root (Figure 5A and B), resulting in
lower mean atherosclerotic lesion area as compared to vehicle (-56%;
Figure 5C). BA sequestration on top of b3-AR agonism strongly attenu-
ated atherosclerotic lesion area by -79% as compared to vehicle; and as
compared to b3-AR agonism alone tended to further reduce the athero-
sclerotic lesion area (-54%; P = 0.16) (Figure 5C). The total plasma TC ex-
posure during the study strongly correlated with the square root
(SQRT)-transformed lesion area (b = 2.14, R2 = 0.40; P < 0.001;
Figure 5D). Moreover, although atherosclerotic lesion severity was not
significantly mitigated by any treatment (Supplementary material online,
Figure S4A), b3-AR agonism increased the proportion of lesion-free
valves as compared to vehicle (þ122%), which was further increased by
additional BA sequestration (þ199% vs. vehicle; þ34% vs. b; Figure 5E).
Proportions of SMC area and collagen area were not affected by any of
the treatments (Figure 5F, G and Supplementary material online, Figure
S4B), while BA sequestration on top of b3-AR agonism further de-
creased the percentage of macrophage area within the lesion (-34% vs.
vehicle; -26% vs. b; Figure 5H and Supplementary material online, Figure
S4B) and increased the stability index defined by the ratio of stable
markers (i.e. SMC area and collagen area) vs. the unstable marker (i.e.
macrophage area) (þ70% vs. vehicle;þ44% vs. b; Figure 5I).
Taken together, BA sequestration in addition to b3-AR agonism tends
to further reduce atherosclerosis development, an effect that is strongly
related to its plasma cholesterol-lowering effect.
4. Discussion
Activating brown fat is a promising strategy to combat hypercholestero-
laemia by increasing the flux of lipoprotein-associated cholesterol to-
wards the liver, thereby exerting atheroprotective effects.7,9 The aim of
this study was first to evaluate the effects of prolonged brown fat activa-
tion, via b3-AR agonism, on hepatic cholesterol turnover. Secondly, we
aimed to assess the effects of BA sequestration on top of brown fat acti-
vation on hepatic cholesterol and BA metabolism as well as atheroscle-
rosis development. We uncovered that the increased hepatic
cholesterol content by prolonged b3-AR agonism as shown previously,17
was accompanied by increased plasma BA levels and decreased faecal
BA excretion. It is likely that more efficient BA reabsorption from the
gut is mostly responsible for these effects, since biliary BA (representing
both newly synthesized BAs and cycled BAs within the enterohepatic
circulation) output was actually increased under these conditions.
Indeed, concomitant BA sequestration by Colesevelam markedly in-
creased faecal BA excretion and lowered the hepatic cholesterol con-
tent. As a result, combining BA sequestration with b3-AR agonism
further reduced plasma cholesterol levels and tended to further reduce
atherosclerosis development and also increase plaque stability as com-
pared to b3-AR agonism alone.
Previously, we observed that prolonged b3-AR agonism in mice
increases the delivery of cholesterol to the liver via the uptake of
cholesterol-enriched TRL remnants7 and HDL-C9 and this increased
flux of cholesterol towards the liver results in a moderate hepatic cho-
lesterol accumulation.17 In fact, 4 weeks of b3-AR agonism already
clearly increased the hepatic cholesterol level. In the current study, we
further show that prolonged b3-AR agonism decreased faecal BA excre-
tion and increased plasma BA levels. Since there is negligible excretion of
BAs via the urine and skin, hepatic BA synthesis from cholesterol equals
faecal BA excretion under steady-state conditions to maintain BA pool
size.24 Our data therefore demonstrate that prolonged b3-AR agonism
decreases hepatic BA synthesis in mice. This is supported by the reduced
expression of genes involved in the classical and alternative BA synthesis
pathways. The observation that the biliary BA secretion rate was not de-
creased after prolonged b3-AR agonism, but rather tended to be in-
creased, can be explained by the fact that the biliary BAs represent both
newly synthesized BAs as well as BAs that are recycled within the enter-
ohepatic circulation. b3-AR agonism increases BA reabsorption from
the gut (i.e. increasing cycled BAs within the enterohepatic circulation),
which is responsible for the overall increased biliary BA output. In line
with our study, Baskin et al.25 recently showed that the b3-AR agonist
mirabegron increased gallbladder size in humans, which could be caused
by an increased BA-induced bile flow upon brown fat activation.
The current study shows that the effects of prolonged brown fat acti-
vation on BA metabolism partly differ from the effects of short-term
brown fat activation. Previous observations by us and others with short-
term brown fat activation by means of b3-AR agonism and cold expo-
sure (i.e. 1 week) showed increased expression of genes related to BA
synthesis18 and increased faecal BA excretion.9,18 This difference ob-
served with treatment duration is likely explained by an initial transient
induction of BA synthesis upon brown fat activation, that is driven by the
increased hepatic influx of cholesterol, the main substrate for BA synthe-
sis,26 and dependent on hepatic induction of Cyp7b1.18 After prolonged
brown fat activation, the higher concentration of BAs in the gut likely
stimulate BA reabsorption from the gut to prevent BA loss from the
body. Subsequently, both BAs in the gut, via induction of FGF15 produc-
tion, and circulating BAs target the hepatic FXR pathway and inhibit BA
synthesis via a well-established feedback mechanism.15 Based on our
findings, 4 weeks of b3-AR agonism is sufficient to induce such an inhibi-
tory feedback on BA synthesis. Collectively, available data indicate that
brown fat activation initially increases BA synthesis and thereby faecal
BA excretion, while prolonged brown fat activation, decreases hepatic
BA synthesis and thereby induces hepatic cholesterol accumulation. It
appears that under these conditions reabsorption of BAs from the gut
becomes more efficient, which, possibly in combination with suppressed
expression of hepatic BA uptake transporters, leads to elevated plasma
levels of BAs. High hepatic cholesterol and BA levels may affect liver
function by inducing liver inflammation.27,28
Since prolonged b3-AR agonism increased plasma levels of BAs, in-
cluding secondary BAs, and decreased faecal BA excretion, we reasoned
that prolonged b3-AR agonism induces reabsorption of BAs from the
gut. In fact, b3-AR agonism clearly increased the expression of Asbt, the






















..predominant transporter for the uptake of the luminal BAs,29 and Ost-b,
a basolateral BA transporter which plays a key role in BA efflux in the il-
eum.30,31 In addition to increasing the expression of BA transporters,
b3-AR agonism increased plasma secondary BA levels. Intestinal anaero-
bic bacteria, i.e. Eubacterium and Clostridium32 are capable to deconjugate
the liver-derived BAs and convert primary BAs into secondary BAs, such
as LCA (omega-MCA in mice) and DCA, which has a high affinity to
ASBT in the ileum.33 The activity of those obligatory anaerobic bacteria
would be largely impaired when faeces were collected and placed in the
presence of oxygen. Thus, the effect of b3-AR agonism on increasing
intestinal BA reabsorption may be attributed to upregulation of Asbt and
Ost-b expression in the ileum as well as increased conversion of primary
BAs into secondary BAs in the gut.
Colesevelam is a BA sequestrant that reduces the reabsorption of
BAs from the gut, with a preference for relatively hydrophobic species
like deoxycholic acid (DCA; i.e. the main secondary BA derived from
CA).26 Likely via this mechanism, Colesevelam particularly increased fae-
cal secondary BA excretion. Interruption of the enterohepatic circula-
tion by a very low dosage of Colesevelam is not complete and increased
hepatic synthesis and sufficient BAs within the circulation resulted in a
Figure 5 Bile acid sequestration on top of b3-AR agonism tends to further attenuate atherosclerosis development. E3L.CETP mice fed a WTD were
treated with vehicle (–), the b3-AR agonist CL316,243 (b), the bile acid sequestrant Colesevelam (c), or their combination (cþ b) for 12 weeks. (A)
Representative pictures of atherosclerotic lesions in aortic root area of each group are shown. (B) Plaque lesion area as a function of distance from the ap-
pearance of open valves and (C) mean atherosclerotic lesion area were calculated. (D) The square root (SQRT) of the mean atherosclerotic lesion area is
plotted against the plasma total cholesterol (TC) exposure during the whole treatment period. (E) Ratio of the number of valves without any lesions divided
by the total number of valves is shown. Relative areas of (F) smooth muscle cells, (G) collagen, and (H) macrophages within the lesion were determined. (I)
The stability index was calculated as the ratio of stable markers (i.e. smooth muscle cell area and collagen area) per unstable marker (i.e. macrophage area).
N = 13–16 mice/group. Values are expressed as means ± SEM. Differences between four groups were determined using one-way ANOVA with the LSD
post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle (–); #P < 0.05 vs. b3-AR agonist (b); $P < 0.05, $$P < 0.01, $$$P < 0.001 vs. Colesevelam (c).


































































































similar biliary BA secretion rate and actually a slightly increased bile flow
as compared to vehicle, which corroborates previous studies.34,35 Most
importantly and fully in line with our expectations, Colesevelam strongly
decreased levels of both hepatic and plasma cholesterol, explained by
the fact that BA elimination is by far the most important contributor to
cholesterol turnover.26 The b3-AR agonism-induced BA reabsorption is
likely effectively inhibited by BA sequestration, as Colesevelam on top of
b3-AR agonism markedly increased faecal excretion of total BAs and
secondary BAs. As a consequence of prevention of reabsorption, plasma
BA levels, in particular secondary BAs were normalized upon BA seques-
tration on top of b3-AR agonism. The fact that BA sequestration on top
of b3-AR agonism still lowered hepatic cholesterol to similar levels as
reached by BA sequestration alone indicates that the effects of BA se-
questration on hepatic cholesterol levels and BA synthesis is stronger
than the effects of b3-AR agonism.
Preclinical studies showed that both b3-AR agonism alone7,17 and the
BA sequestrant Colesevelam alone35 not only reduce plasma cholesterol
levels but also atherosclerosis development. Importantly, we now show
that BA sequestration on top of b3-AR agonism further reduces plasma
non-HDL-C levels, tended to further reduce atherosclerosis develop-
ment and further increased plaque stability as evidenced by reduced
macrophage area versus SMC and collagen area within the lesion. This
finding is highly relevant from a clinical perspective. In humans, the b3-
AR agonist Mirabegron increases brown fat activity and resting energy
expenditure36 and high brown fat activity is associated with a reduced
risk of cardiovascular disease events.37 In addition, BA sequestrants at-
tenuate coronary heart disease38 and coronary artery lesions in
humans.39 Based on our findings, we speculate that combining conven-
tional lipid-lowering by BA sequestration with brown fat activation may
further improve dyslipidaemia and reduce atherosclerosis development
in clinic.
In conclusion, prolonged b3-AR agonism promotes BA reabsorption
from the gut, resulting in elevated plasma BA levels, suppressed hepatic
BA synthesis and elevated hepatic cholesterol content. Concomitant BA
sequestration on top of b3-AR agonism increases faecal BA excretion,
normalizes plasma BA levels, reverses the b3-AR agonism-induced he-
patic cholesterol accumulation, further lowers plasma non-HDL-C levels
and tends to further lower atherosclerosis development. These data sug-
gest that combining conventional BA sequestration with brown fat acti-
vation via b3-AR agonism could be a new therapeutic strategy to further
reduce dyslipidaemia and attenuate atherosclerosis development.
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Translational perspective
Current therapeutic strategies are unable to prevent the majority of cardiovascular disease (CVD)-relating morbidities and mortalities, illustrating the
need for new therapeutic strategies. Brown fat has been shown as an emerging target to combat hyperlipidaemia and atherosclerosis. Here, we
showed that prolonged brown fat activation promotes bile acid (BA) reabsorption, resulting in elevated plasma BA and hepatic cholesterol content,
both of which are reversed by additional BA sequestration. Importantly, combining BA sequestration with brown fat activation further lowers plasma
cholesterol and reduces atherosclerosis development, indicating the combination therapy as a new therapeutic strategy to treat hyperlipidaemia, and
ultimately CVD.
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